Which class of medications is NOT listed as a weight neutral option for migraine management?

Valproic acid is recognized as a medication that can potentially lead to weight gain, making it less favorable for individuals concerned about weight management during migraine treatment. In contrast, NSAIDs, triptans, and CGRP antagonists are generally considered weight-neutral options.

NSAIDs, such as ibuprofen and naproxen, are primarily anti-inflammatory medications and do not have a significant impact on body weight. Triptans, which work by narrowing blood vessels in the brain and alleviating migraine symptoms, are also not associated with weight changes. Furthermore, CGRP antagonists, a newer class of migraine treatments, have been studied and shown to have a minimal effect on weight, making them suitable for patients managing both migraines and obesity or weight concerns.

With valproic acid's association with weight gain, it stands apart from the other options recognized for their neutrality in weight management while treating migraines.